AtriCure (NASDAQ:ATRC) Issues FY 2026 Earnings Guidance

AtriCure (NASDAQ:ATRC) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.090-0.150 for the period, compared to the consensus EPS estimate of -0.030. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.3 million.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, January 21st. Wall Street Zen raised shares of AtriCure from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 21st. Canaccord Genuity Group reduced their price target on AtriCure from $64.00 to $53.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. Oppenheimer downgraded AtriCure from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 18th. Finally, Citizens Jmp cut their price objective on AtriCure from $60.00 to $52.00 and set a “market outperform” rating for the company in a research report on Wednesday, February 18th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.43.

AtriCure Trading Down 1.1%

Shares of ATRC stock opened at $30.93 on Tuesday. AtriCure has a 12-month low of $28.29 and a 12-month high of $43.18. The company has a market capitalization of $1.54 billion, a PE ratio of -128.88 and a beta of 1.42. The firm has a 50 day moving average price of $37.06 and a two-hundred day moving average price of $36.52. The company has a quick ratio of 2.99, a current ratio of 3.96 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Tuesday, February 17th. The medical device company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. The company had revenue of $140.50 million for the quarter, compared to analyst estimates of $140.50 million. AtriCure had a negative return on equity of 1.15% and a negative net margin of 2.14%.The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.33) earnings per share. As a group, analysts predict that AtriCure will post -0.6 earnings per share for the current year.

Hedge Funds Weigh In On AtriCure

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP increased its position in AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock worth $151,296,000 after acquiring an additional 322,818 shares during the period. First Light Asset Management LLC grew its position in shares of AtriCure by 32.0% during the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after purchasing an additional 285,083 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of AtriCure by 8.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 921,897 shares of the medical device company’s stock worth $36,472,000 after purchasing an additional 71,341 shares during the period. Marshall Wace LLP increased its holdings in shares of AtriCure by 63.4% during the fourth quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock worth $36,136,000 after purchasing an additional 354,281 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of AtriCure by 13.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 885,062 shares of the medical device company’s stock valued at $35,013,000 after buying an additional 107,754 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.